822 related articles for article (PubMed ID: 21319944)
1. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
Sostek MB; Fort JG; Estborn L; Vikman K
Curr Med Res Opin; 2011 Apr; 27(4):847-54. PubMed ID: 21319944
[TBL] [Abstract][Full Text] [Related]
2. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
Cryer BL; Sostek MB; Fort JG; Svensson O; Hwang C; Hochberg MC
Ann Med; 2011 Dec; 43(8):594-605. PubMed ID: 22017620
[TBL] [Abstract][Full Text] [Related]
3. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
Angiolillo DJ; Datto C; Raines S; Yeomans ND
J Thromb Thrombolysis; 2014 Jul; 38(1):11-23. PubMed ID: 24368727
[TBL] [Abstract][Full Text] [Related]
4. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
5. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
Scheiman JM; Yeomans ND; Talley NJ; Vakil N; Chan FK; Tulassay Z; Rainoldi JL; Szczepanski L; Ung KA; Kleczkowski D; Ahlbom H; Naesdal J; Hawkey C
Am J Gastroenterol; 2006 Apr; 101(4):701-10. PubMed ID: 16494585
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
7. Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Bello AE; Kent JD; Grahn AY; Rice P; Holt RJ
Postgrad Med; 2014 Jul; 126(4):82-91. PubMed ID: 25141246
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone.
Goldstein JL; Hochberg MC; Fort JG; Zhang Y; Hwang C; Sostek M
Aliment Pharmacol Ther; 2010 Aug; 32(3):401-13. PubMed ID: 20497139
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
10. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
11. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial.
Goldstein JL; Johanson JF; Suchower LJ; Brown KA
Am J Gastroenterol; 2005 Dec; 100(12):2650-7. PubMed ID: 16393215
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
13. Diclofenac/misoprostol: the European clinical experience.
McKenna F
J Rheumatol Suppl; 1998 May; 51():21-30. PubMed ID: 9596551
[TBL] [Abstract][Full Text] [Related]
14. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
Lovell DJ; Dare JA; Francis-Sedlak M; Ball J; LaMoreaux BD; Von Scheven E; Reinhardt A; Jerath R; Alpan O; Gupta R; Goldsmith D; Zeft A; Naddaf H; Gottlieb B; Jung L; Holt RJ
Pediatr Rheumatol Online J; 2018 Jun; 16(1):41. PubMed ID: 29941047
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
Wang-Smith L; Fort J; Zhang Y; Sostek M
J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
[TBL] [Abstract][Full Text] [Related]
17. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
Taha AS; Hudson N; Hawkey CJ; Swannell AJ; Trye PN; Cottrell J; Mann SG; Simon TJ; Sturrock RD; Russell RI
N Engl J Med; 1996 May; 334(22):1435-9. PubMed ID: 8618582
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin.
Yeomans N; Lanas A; Labenz J; van Zanten SV; van Rensburg C; Rácz I; Tchernev K; Karamanolis D; Roda E; Hawkey C; Nauclér E; Svedberg LE
Am J Gastroenterol; 2008 Oct; 103(10):2465-73. PubMed ID: 18637091
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers.
Miner P; Plachetka J; Orlemans E; Fort JG; Sostek M
Aliment Pharmacol Ther; 2010 Aug; 32(3):414-24. PubMed ID: 20491746
[TBL] [Abstract][Full Text] [Related]
20. A double blind study comparing the efficacy and safety of enteric coated naproxen to naproxen in the management of NSAID intolerant patients with rheumatoid arthritis and osteoarthritis. Naproxen EC Study Group.
Caldwell JR; Roth SH
J Rheumatol; 1994 Apr; 21(4):689-95. PubMed ID: 8035394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
